Stem cell therapy for lung diseases is real research with genuine promise, but it has not yet crossed the finish line into routine clinical use. Dozens of clinical trials have tested mesenchymal stem cells (MSCs) in conditions like acute respiratory distress syndrome, pulmonary fibrosis, and COPD, and the results so far show a consistent pattern: the treatments appear safe, inflammation often drops, but hard endpoints like survival and long-term lung function improvement remain difficult to prove. The science behind why stem cells help injured lungs turns out to be more surprising than most people expect, and so does the gap between what clinics advertise and what the evidence actually supports.
How Stem Cells Work in the Lungs
The early hope was straightforward: inject stem cells into damaged lungs and they would settle in, multiply, and replace destroyed tissue. That is not what happens. When researchers tracked MSCs after intravenous infusion, the vast majority got trapped in the lung’s tiny blood vessels almost immediately, and very few survived long enough to integrate into the tissue in any meaningful way. Instead, the therapeutic effects seem to come from what the cells release rather than what they become. MSCs secrete a cocktail of signaling molecules, growth factors, and tiny membrane-bound packages called exosomes that together calm inflammation, reduce fluid buildup in the air sacs, and nudge the lung’s own repair processes into action.
This “paracrine” mechanism was a paradigm shift for the field. Researchers found that MSCs reduce the permeability of the barriers lining the lung’s airways and blood vessels, help clear excess fluid from the alveoli, and tamp down the overactive immune responses that cause much of the damage in conditions like ARDS.1PubMed Central. Paracrine factors from mesenchymal stem cells: a proposed therapeutic tool for acute lung injury and acute respiratory distress syndrome Crucially, these benefits occur without the stem cells actually settling permanently in the lung, which points strongly toward the secreted factors doing most of the work.2PubMed Central. Stem cell-derived extracellular vesicles: a potential intervention for Bronchopulmonary Dysplasia This insight has pushed research in a new direction: if the cells’ secretions are what matter, maybe you can skip the cells entirely and just deliver the secretions. More on that below.
The Lung’s Own Stem Cells
Your lungs already have built-in stem cells. The most important are alveolar type 2 (AT2) cells, which sit in the tiny air sacs where oxygen exchange happens.3PubMed. Tracing the origin of alveolar stem cells in lung repair and regeneration AT2 cells can copy themselves and also transform into the flat alveolar type 1 (AT1) cells that line most of the air sac surface. When the lung is injured, AT2 cells ramp up to replace what was lost. In diseases like idiopathic pulmonary fibrosis and COPD, though, these native stem cells malfunction, and the repair process goes haywire, producing scar tissue instead of functional lung.4PubMed Central. Unlocking Alveolar Regeneration: AT2 Stem Cells, Signaling Networks, and Therapeutic Frontiers
A separate population, basal cells, serves as the stem cells of the airway lining higher up in the bronchial tree. Lab teams have learned to grow both AT2-like cells and airway basal cells from induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed back to an embryonic-like state. Researchers have coaxed iPSCs through a sequence of chemical signals to produce functional airway organoids, miniature lung-like structures that mimic the real thing well enough to use for drug screening and disease modeling.5PubMed Central. Efficient Derivation of Functional Human Airway Epithelium from Pluripotent Stem Cells via Temporal Regulation of Wnt Signaling Another group reported generating airway basal cells from iPSCs that resemble the natural stem cell of the airway epithelium.6Cell Stem Cell. Derivation of Airway Basal Stem Cells from Human Pluripotent Stem Cells These lab-grown cells are not being transplanted into patients yet, but they are already valuable for understanding what goes wrong in lung disease and for testing potential drugs.
Getting Cells to the Right Place
Delivery is one of the trickiest problems in lung stem cell therapy. The most common approach in clinical trials is intravenous infusion, which is simple but has a major drawback: the lung acts as a filter. MSCs are relatively large cells, and when they hit the fine capillary network in the lungs, most of them get stuck there. One study found that the vast majority of MSCs were trapped in the lungs within seconds of IV injection, with only a small fraction making it through to the rest of the body.7PubMed Central. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect The diameter of suspended MSCs measures roughly 15 to 19 micrometers, far too large to pass easily through pulmonary capillaries.8PubMed. Stem cell transplantation: the lung barrier
For lung diseases specifically, this “first-pass trapping” could theoretically be an advantage: the cells end up right where you want them. But getting stuck in blood vessels is not the same as integrating into damaged tissue, and many of those trapped cells die quickly. Researchers have experimented with vasodilators to reduce trapping, split-dose infusions, and direct intratracheal delivery, where cells are placed straight into the airways. A newer approach bypasses whole cells altogether, using nebulized exosomes or secretome (the full set of factors cells release) inhaled through a standard nebulizer. Animal studies have shown that nebulized material reaches the deep lung tissue and can reduce inflammation and fibrosis in COPD and pulmonary fibrosis models.9PubMed. Nebulized mesenchymal stem cell-derived exosomes attenuate airway inflammation in a rat model of chronic obstructive pulmonary disease Inhalable exosome formulations are now being studied for targeted respiratory delivery with fewer systemic side effects.10PubMed Central. Inhalable Exosomes in Respiratory Therapies with the Transformative Potential
What Clinical Trials Have Found So Far
The clinical evidence is most developed for three lung conditions: ARDS, idiopathic pulmonary fibrosis (IPF), and COPD. The findings share a pattern that is both encouraging and frustrating.
Acute Respiratory Distress Syndrome
ARDS is the condition where stem cells have the strongest theoretical rationale, because the damage is acute, inflammation-driven, and potentially reversible if you can calm the immune storm fast enough. Preclinical animal studies have consistently shown dramatic benefits. In human trials, MSC infusions have proven safe at doses up to 10 million cells per kilogram of body weight, with no significant infusion-related toxicity even after multiple doses. But while some trials have shown drops in inflammatory markers and improvements in markers of lung repair, a clear mortality benefit has not been conclusively demonstrated across the board. Some subgroup analyses suggest that younger patients and those who receive higher doses of viable cells may benefit more.11PubMed Central. Mesenchymal stem cell therapies for ARDS: translational promise and challenges
During the COVID-19 pandemic, multiple teams tried MSC therapy in patients with severe SARS-CoV-2-related ARDS. A systematic review found that cell therapy reduced levels of the inflammatory marker IL-6 in about half of the studies that measured it, and reduced TNF-alpha levels in roughly 70% of those studies.12npj Regenerative Medicine. Stem cell-based therapy for COVID-19 and ARDS: a systematic review The ability to dampen the cytokine storm was real, but translating that into survival improvements proved harder than expected.
Idiopathic Pulmonary Fibrosis
IPF is a progressive scarring disease with no cure and limited treatment options. Several early-phase trials have tested MSC infusions in these patients. A Phase 1 safety trial using bone marrow-derived MSCs found no treatment-emergent serious adverse events; by 60 weeks after infusion, patients showed a modest decline in lung function measurements, roughly what you would expect from the natural progression of the disease.13PubMed Central. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial A separate Phase 1b trial using placenta-derived MSCs also found the infusions well tolerated, with lung function, exercise capacity, and CT fibrosis scores unchanged from baseline at six months, suggesting the treatment at least did not accelerate the disease.14PubMed. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis
The most encouraging IPF trial to date used higher cumulative doses in patients whose lung function was declining rapidly. The MSC-treated group saw their forced vital capacity (a key measure of lung volume) increase by about 8% from baseline over 12 months, while the placebo group’s FVC dropped by about 6%. Exercise capacity and gas exchange also improved in the treatment group. Two patients died in each group, so there was no mortality difference, but the functional improvements were striking for a disease that normally only gets worse.15PubMed Central. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline
Chronic Obstructive Pulmonary Disease
COPD results have been more sobering. The largest placebo-controlled trial found that IV-infused MSCs did not improve lung function tests or quality-of-life scores compared to placebo. The one bright spot: patients with elevated baseline levels of C-reactive protein (a marker of systemic inflammation) did show a significant early drop in CRP after MSC treatment.16Chest. A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD A pilot study using umbilical cord-derived MSCs found improvements in symptom scores and a reduction in the number of acute flare-ups, but airflow measurements and inflammatory markers did not change significantly.17PubMed Central. Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study COPD involves structural destruction of lung tissue that has been building for years or decades, and asking stem cells to reverse that kind of damage may simply be a bigger ask than calming an acute inflammatory episode.
Safety Concerns That Matter
Across most clinical trials, MSC infusions have been remarkably well tolerated. No consistent pattern of serious adverse events has emerged. But “safe in a controlled trial” is not the same as “risk-free,” and a few concerns deserve attention.
The most significant biological risk is clotting. MSCs express a protein called tissue factor on their surface, and when these cells contact blood, they can trigger the coagulation cascade. In some animal experiments, this has led to blood clots in the lungs. One mouse study documented roughly 85% mortality within 24 hours of intravenous infusion of adipose-derived stem cells, directly caused by pulmonary embolism. Blocking tissue factor with an antibody suppressed this procoagulant activity.18PubMed. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism Human trials have not seen this catastrophic outcome, likely because of dose differences and anticoagulant precautions, but the thrombogenic risk is taken seriously in trial design. Some researchers describe a dual activation of both coagulation and complement pathways, called the instant blood-mediated inflammatory reaction, which may also explain why engraftment rates in clinical trials tend to be low.19PubMed Central. Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives
For iPSC-derived cells, tumor formation has long been the nightmare scenario, since these cells are reprogrammed to a state close to embryonic. The reassuring news is that once iPSCs are differentiated into lung progenitor cells or mature alveolar-like cells, they do not form tumors in animal testing. One study found that neither lung progenitors nor terminally differentiated alveolar-like cells produced teratomas, and that the expression of two tumor-suppressor proteins actually increased more than 3,000-fold during differentiation.20PubMed. Assessment of iPSC teratogenicity throughout directed differentiation toward an alveolar-like phenotype Another study confirmed that disseminated iPSCs did not form teratomas within 180 days in mice, even at doses 50 times the standard amount and even in animals with severe lung injury.21PubMed Central. Direct in vivo application of induced pluripotent stem cells is feasible and can be safe
Skipping the Cells Entirely
If the therapeutic benefit comes primarily from what stem cells secrete rather than the cells themselves, the logical next step is to deliver those secretions directly. This cell-free approach is gaining momentum. Researchers have tested inhaled secretome and exosomes from lung spheroid cells and MSCs in animal models of pulmonary fibrosis. Both reduced scarring and preserved the architecture of the air sacs, though the lung spheroid cell secretome outperformed the MSC version in all measures tested.22Nature Communications. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
Cell-free approaches have practical advantages that could accelerate their path to the clinic. Exosomes are smaller and less likely to trigger clotting or immune rejection. They can be manufactured in batches, stored, and delivered through a simple nebulizer at home. They avoid the regulatory and biological complexities of keeping live cells viable during transport and infusion. The tradeoff is that exosomes probably cannot do everything a living cell can: a cell can sense its environment and adjust its output, while an exosome package delivers a fixed payload. Whether that matters for clinical outcomes is still an open question.
Gene Editing for Cystic Fibrosis
One of the most compelling applications of lung stem cell science sits at the intersection of stem cells and gene editing. Cystic fibrosis is caused by mutations in a single gene, which makes it a theoretically ideal target: fix the gene in the lung’s own stem cells and the repair could be permanent. Two research groups have made significant progress on this front.
One team used CRISPR-Cas9 and a viral delivery vehicle to correct the most common CF mutation (called ΔF508) directly in upper-airway basal stem cells taken from CF patients. They achieved correction in roughly 30% to 50% of the gene copies and restored about 20% to 50% of normal CFTR protein function when those cells were grown into differentiated airway tissue.23Cell Stem Cell. Selection-Free Genome Editing of Upper Airway Basal Cells to Treat Cystic Fibrosis A second team developed a strategy that works regardless of which specific CF mutation a patient carries, inserting a full-length corrected copy of the gene into the right spot in airway basal stem cells. When those corrected cells were grown into airway tissue, they restored about 70% to 80% of normal chloride transport, the function that CF disrupts.24Molecular Therapy. Universal correction of the CFTR locus in airway stem cells for cystic fibrosis
Both approaches remain in the lab for now. The challenge is getting corrected cells back into a living patient’s airways in a way that lets them take hold and repopulate the tissue. But the gene-editing efficiency is high enough that a viable clinical therapy seems within reach, not in some distant theoretical future but as an active area of translational research.
The Unproven Clinic Problem
While legitimate researchers work through clinical trials, a parallel industry has sprung up offering stem cell “treatments” for lung disease outside any regulatory framework. Clinics around the world market stem cell injections or infusions for COPD, pulmonary fibrosis, and other conditions, typically charging thousands of dollars out of pocket. These treatments are generally unproven and in some cases have no supporting evidence at all.25Respiratory Therapy. Increase in Unproven Stem Cell Therapies for Lung Disease
The marketing often blurs the line between what published research has shown in tightly controlled settings and what a given clinic is actually offering. A clinic might cite legitimate animal studies or early-phase human trials as evidence, without mentioning that those studies used different cell types, different doses, different delivery routes, or different patient populations than whatever the clinic provides. For someone with progressive lung disease and limited options, the appeal is understandable, but the risks are real: unregulated cell preparations can carry contaminants, trigger immune reactions, or cause harm that a properly designed trial would catch early. The FDA and international regulatory bodies have repeatedly warned consumers about these operations.
Building Lungs From Scratch
The most ambitious application of stem cells in lung medicine is whole-organ bioengineering. The concept is to take a donor lung, strip away all its living cells with detergent solutions (decellularization), leaving behind a protein scaffold that retains the organ’s branching architecture, and then reseed that scaffold with a patient’s own stem cells (recellularization).26PubMed Central. Lung bioengineering: advances and challenges in lung decellularization and recellularization The goal is a transplantable lung that would not trigger immune rejection.
Researchers have made progress on the decellularization side, successfully processing human-sized lung scaffolds.27PubMed. Decellularized human-sized pulmonary scaffolds for lung tissue engineering: a comprehensive review The recellularization side remains extraordinarily difficult. The lung has more than 40 distinct cell types arranged in a precise three-dimensional layout, and getting lab-grown cells to populate the scaffold correctly, form functioning air-blood barriers, and sustain gas exchange is a problem that has not been solved. Bioengineered lungs have been transplanted in a small number of animal experiments, but the organs have not maintained function for long. This is a decades-away prospect for human patients, not something on the near-term horizon.
Lung Organoids and Drug Discovery
While clinical stem cell therapy works through its growing pains, one area where stem cells are already delivering tangible value is disease modeling. Researchers have built alveolar organoids, tiny three-dimensional lung-like structures, from human pluripotent stem cells mixed with primary lung fibroblasts. When treated with the scarring agent bleomycin, these organoids developed features that mirror pulmonary fibrosis: abnormal cell activation, premature cell aging, and accumulation of scar-like material. The team then screened potential drugs against the organoids and found compounds that reversed the fibrotic changes.28Stem Cell Reports. Establishment of a human alveolar organoid model to study fibroblast-epithelial interactions in pulmonary fibrosis
This kind of work matters because lung fibrosis drug development has historically relied on animal models that do not faithfully replicate the human disease. Mice, for instance, can clear bleomycin-induced fibrosis on their own, which humans obviously cannot. Human organoids offer a platform that captures the cell-to-cell interactions driving fibrosis in human tissue, speeds up screening, and could help identify drug candidates that would otherwise be missed or falsely rejected in animal testing. It is less dramatic than the idea of regrowing a lung, but it may end up helping more patients sooner.
Tracking Cells After Delivery
One of the persistent challenges in the field is simply knowing where stem cells go after they are delivered and how long they survive. Without that information, it is hard to optimize doses, timing, or delivery routes. Several imaging strategies have been developed to address this. One team used gadolinium-based contrast agents to label stem cells and track them with MRI as they homed to injured lung tissue over extended periods.29PubMed Central. Use of trimetasphere metallofullerene MRI contrast agent for the non-invasive longitudinal tracking of stem cells in the lung Another group developed a dual-labeling approach combining gold nanoparticle-based CT imaging with bioluminescence tracking, allowing them to see both where transplanted MSCs ended up and whether they were still alive in a pulmonary fibrosis model.30PubMed. CT/Bioluminescence Dual-Modal Imaging Tracking of Mesenchymal Stem Cells in Pulmonary Fibrosis A third approach used fiber-optic probes inserted through a tiny chest incision to image cells in the deep lung in real time.31Scientific Reports. Controlled delivery and minimally invasive imaging of stem cells in the lung These tools are still mostly confined to animal research, but they are filling in knowledge gaps about cell fate that clinical trials alone cannot answer.